Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases

BACKGROUND: Considering the considerable prevalence of allergic disease in the general population, an urgent need exists for inactivated SARS-CoV-2 vaccines that can be safely administered to those subjects. METHODS: This retrospective cohort study including 1926 participants who received inactivate...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Chao, Qiu, Feng, Lou, Chengcheng, Fang, Lingling, Liu, Fang, Zhong, Jingjing, Sun, Weijie, Ding, Weiping, Yu, Xiaopin, Xu, Qinhong, Wang, Ran, Ruan, Liemin, Song, Qifa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137440/
https://www.ncbi.nlm.nih.gov/pubmed/35624516
http://dx.doi.org/10.1186/s12931-022-02054-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137440/
https://www.ncbi.nlm.nih.gov/pubmed/35624516
http://dx.doi.org/10.1186/s12931-022-02054-1

Ejemplares similares